Security key
55083R104
Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (LYEL)
CUSIP: 55083R104
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock par value $0.0001 per share
- Shares outstanding
- 23,360,878
- Total 13F shares
- 650,353
- Share change
- -1,790,320
- Total reported value
- $10,561,733
- Price per share
- $16.24
- Number of holders
- 2
- Value change
- -$15,728,473
- Number of buys
- 1
- Number of sells
- 4
Report period
Q3 2025
Institutions
2
Top holders
2
LYEL full security history
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Lyell Immunopharma, Inc. SEC filings
Lyell Immunopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 55083R104
Recent filing periods:
Top shareholders of LYEL - Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Robert Nelsen |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
36,542,716
mixed-class rows
|
$83,020,992 | — | 14 Jun 2024 | |
| GSK plc |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
30,253,189
|
$68,977,271 | — | 21 Jun 2021 | |
| ARCH Venture Fund IX, L.P. |
13D/G
|
— |
13%
|
2,759,072
|
$44,807,053 | $0 | 30 Sep 2025 | |
| Foresite Capital Fund IV, L.P. |
13D/G
|
James B. Tananbaum |
7.6%
|
1,454,616
|
$23,622,818 | $0 | 30 Sep 2025 | |
| ARCH Venture Management, LLC |
13F
|
Company |
9.5%
|
1,820,634
|
$16,112,611 | — | 30 Jun 2025 | |
| NEWTON (PTC) Ltd |
13D/G
|
Newton (PTC) Limited |
3.9%
|
754,698
|
$12,256,220 | $0 | 30 Sep 2025 | |
| Hans Edgar Bishop |
3/4/5
|
Director |
—
mixed-class rows
|
4,815,614
mixed-class rows
|
$10,683,200 | — | 14 Jun 2024 | |
| Gates Frontier, LLC |
13D/G
|
— |
5.6%
|
1,040,964
|
$10,628,242 | $0 | 25 Jul 2025 | |
| MWG Management Ltd. |
13F
|
Company |
4.3%
|
1,008,116
|
$8,911,745 | — | 30 Jun 2025 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
4.2%
|
800,399
|
$7,075,527 | — | 30 Jun 2025 | |
| Orland Properties Ltd |
13F
|
Company |
3.2%
|
754,698
|
$6,671,530 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
4.5%
|
13,265,869
|
$6,234,958 | $0 | 31 Dec 2024 | |
| Decheng Capital LLC |
13F
|
Company |
2.5%
|
595,466
|
$5,263,919 | — | 30 Jun 2025 | |
| Almitas Capital LLC |
13F
|
Company |
3%
|
579,997
|
$5,127,173 | — | 30 Jun 2025 | |
| venBio Partners LLC |
13F
|
Company |
2.5%
|
473,479
|
$4,185,554 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.3%
|
442,626
|
$3,912,814 | — | 30 Jun 2025 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
2.1%
|
406,652
|
$3,594,804 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.6%
|
306,059
|
$2,706,000 | — | 30 Jun 2025 | |
| Alphabet Inc. |
13F
|
Company |
1.5%
|
293,256
|
$2,592,383 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.4%
|
271,283
|
$2,398,142 | — | 30 Jun 2025 | |
| Richard Klausner |
3/4/5
|
Director |
—
mixed-class rows
|
4,071,199
mixed-class rows
|
$1,791,262 | — | 15 May 2025 | |
| HSG Holding Ltd |
13F
|
Company |
0.8%
|
152,299
|
$1,346,321 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.54%
|
103,270
|
$913,261 | — | 30 Jun 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.52%
|
100,000
|
$884,000 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.51%
|
98,425
|
$870,077 | — | 30 Jun 2025 | |
| MIC Capital Management UK LLP |
13F
|
Company |
0.45%
|
87,028
|
$769,328 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.35%
|
67,190
|
$593,960 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.32%
|
61,503
|
$543,687 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.27%
|
52,229
|
$461,704 | — | 30 Jun 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.27%
|
51,727
|
$457,267 | — | 30 Jun 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.26%
|
50,232
|
$444,051 | — | 30 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.23%
|
43,799
|
$387,183 | — | 30 Jun 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.18%
|
41,165
|
$368,015 | — | 30 Jun 2025 | |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
|
Company |
0.18%
|
41,165
|
$363,906 | — | 30 Jun 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.21%
|
39,621
|
$350,250 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.18%
|
33,847
|
$299,207 | — | 30 Jun 2025 | |
| Charles W. Newton |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
81,556
mixed-class rows
|
$290,086 | -$18,105 | 20 Aug 2025 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
0.15%
|
29,411
|
$259,993 | — | 30 Jun 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.15%
|
29,230
|
$258,393 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.14%
|
27,366
|
$241,000 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.13%
|
25,698
|
$227,170 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.13%
|
25,634
|
$226,605 | — | 30 Jun 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.13%
|
24,419
|
$215,864 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.12%
|
23,758
|
$210,021 | — | 30 Jun 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.11%
|
21,700
|
$191,828 | — | 30 Jun 2025 | |
| Clarius Group, LLC |
13F
|
Company |
0.1%
|
19,138
|
$169,180 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.1%
|
18,644
|
$164,813 | — | 30 Jun 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.09%
|
18,000
|
$159,120 | — | 30 Jun 2025 | |
| Cathy Friedman |
3/4/5
|
Director |
—
mixed-class rows
|
596,370
mixed-class rows
|
$158,093 | — | 15 May 2025 | |
| Matthew Lang |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
218,750
mixed-class rows
|
$114,000 | — | 10 Feb 2025 |
Institutional Holders of Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (LYEL) as of Q3 2025
As of 30 Sep 2025,
Lyell Immunopharma, Inc. - Common Stock par value $0.0001 per share (LYEL) was held by
2 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
650,353 shares.
The largest 2 holders included
Decheng Capital LLC and TAKEDA PHARMACEUTICAL CO LTD.
This page lists
2
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
6
Q3 2025 holders
2
Holder diff
-4
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.